BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31967940)

  • 1. SPOP is essential for DNA-protein cross-link repair in prostate cancer cells: SPOP-dependent removal of topoisomerase 2A from the topoisomerase 2A-DNA cleavage complex.
    Watanabe R; Maekawa M; Hieda M; Taguchi T; Miura N; Kikugawa T; Saika T; Higashiyama S
    Mol Biol Cell; 2020 Mar; 31(6):478-490. PubMed ID: 31967940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depletion of tyrosyl DNA phosphodiesterase 2 activity enhances etoposide-mediated double-strand break formation and cell killing.
    Kont YS; Dutta A; Mallisetty A; Mathew J; Minas T; Kraus C; Dhopeshwarkar P; Kallakury B; Mitra S; Üren A; Adhikari S
    DNA Repair (Amst); 2016 Jul; 43():38-47. PubMed ID: 27235629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
    Zhu Y; Wen J; Huang G; Mittlesteadt J; Wen X; Lu X
    Prostate; 2021 Jan; 81(1):81-88. PubMed ID: 33022763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Roles of SPOP in DNA Damage Response and DNA Replication.
    Maekawa M; Higashiyama S
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. G3BP1 inhibits Cul3
    Mukhopadhyay C; Yang C; Xu L; Liu D; Wang Y; Huang D; Deonarine LD; Cyrta J; Davicioni E; Sboner A; Robinson BD; Chinnaiyan AM; Rubin MA; Barbieri CE; Zhou P
    Nat Commun; 2021 Nov; 12(1):6662. PubMed ID: 34795264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
    Shi L; Yan Y; He Y; Yan B; Pan Y; Orme JJ; Zhang J; Xu W; Pang J; Huang H
    Cancer Res; 2021 Jul; 81(13):3593-3606. PubMed ID: 33762355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
    Geng C; He B; Xu L; Barbieri CE; Eedunuri VK; Chew SA; Zimmermann M; Bond R; Shou J; Li C; Blattner M; Lonard DM; Demichelis F; Coarfa C; Rubin MA; Zhou P; O'Malley BW; Mitsiades N
    Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6997-7002. PubMed ID: 23559371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mre11 Is Essential for the Removal of Lethal Topoisomerase 2 Covalent Cleavage Complexes.
    Hoa NN; Shimizu T; Zhou ZW; Wang ZQ; Deshpande RA; Paull TT; Akter S; Tsuda M; Furuta R; Tsutsui K; Takeda S; Sasanuma H
    Mol Cell; 2016 Nov; 64(3):580-592. PubMed ID: 27814490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of TDP2 on the Level of TOP2-DNA Complexes and SUMOylated TOP2-DNA Complexes.
    Lee KC; Swan RL; Sondka Z; Padget K; Cowell IG; Austin CA
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.
    Jin X; Wang J; Gao K; Zhang P; Yao L; Tang Y; Tang L; Ma J; Xiao J; Zhang E; Zhu J; Zhang B; Zhao SM; Li Y; Ren S; Huang H; Yu L; Wang C
    PLoS Genet; 2017 Apr; 13(4):e1006748. PubMed ID: 28448495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP-HIPK2 axis.
    Jin X; Qing S; Li Q; Zhuang H; Shen L; Li J; Qi H; Lin T; Lin Z; Wang J; Cao X; Yang J; Ma Q; Cong L; Xi Y; Fang S; Meng X; Gong Z; Ye M; Wang S; Wang C; Gao K
    Nucleic Acids Res; 2021 Jul; 49(12):6788-6803. PubMed ID: 34133717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
    Geng C; Kaochar S; Li M; Rajapakshe K; Fiskus W; Dong J; Foley C; Dong B; Zhang L; Kwon OJ; Shah SS; Bolaki M; Xin L; Ittmann M; O'Malley BW; Coarfa C; Mitsiades N
    Oncogene; 2017 Aug; 36(33):4767-4777. PubMed ID: 28414305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
    Yan Y; Ma J; Wang D; Lin D; Pang X; Wang S; Zhao Y; Shi L; Xue H; Pan Y; Zhang J; Wahlestedt C; Giles FJ; Chen Y; Gleave ME; Collins CC; Ye D; Wang Y; Huang H
    EMBO Mol Med; 2019 Nov; 11(11):e10659. PubMed ID: 31559706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.
    Wu F; Dai X; Gan W; Wan L; Li M; Mitsiades N; Wei W; Ding Q; Zhang J
    Cancer Lett; 2017 Jan; 385():207-214. PubMed ID: 27780719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.
    Wang H; Barbieri CE; He J; Gao Y; Shi T; Wu C; Schepmoes AA; Fillmore TL; Chae SS; Huang D; Mosquera JM; Qian WJ; Smith RD; Srivastava S; Kagan J; Camp DG; Rodland KD; Rubin MA; Liu T
    J Transl Med; 2017 Aug; 15(1):175. PubMed ID: 28810879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants.
    Zhang P; Gao K; Tang Y; Jin X; An J; Yu H; Wang H; Zhang Y; Wang D; Huang H; Yu L; Wang C
    Hum Mutat; 2014 Sep; 35(9):1142-51. PubMed ID: 24990631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
    Luo Z; Wang J; Zhu Y; Sun X; He C; Cai M; Ma J; Wang Y; Han S
    Neoplasia; 2021 Oct; 23(10):1037-1047. PubMed ID: 34509929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
    Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
    Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants.
    An J; Wang C; Deng Y; Yu L; Huang H
    Cell Rep; 2014 Feb; 6(4):657-69. PubMed ID: 24508459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.
    Theurillat JP; Udeshi ND; Errington WJ; Svinkina T; Baca SC; Pop M; Wild PJ; Blattner M; Groner AC; Rubin MA; Moch H; Prive GG; Carr SA; Garraway LA
    Science; 2014 Oct; 346(6205):85-89. PubMed ID: 25278611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.